Novel Surrogate Marker Described for Pancreatic Neuroendocrine Tumors
|
By LabMedica International staff writers Posted on 19 May 2022 |

Tumors of the endocrine pancreas are a collection of tumor cell types collectively referred to as PanNETs. These tumors originate in islet cells. Although they may be similar or identical in histologic appearance to carcinoid tumors of the gastrointestinal tract, differences in their underlying biology and likely differences in response to therapeutic agents suggest that they should be treated and investigated as a distinct entity.
Pancreatic neuroendocrine tumor (PanNET) is the second most common solid neoplasm of the pancreas, accounting for 3% to 4% of all pancreas neoplasms. The incidence of this tumor has increased owing to advances in various imaging techniques and increasing awareness. Surgical resection is the main treatment option for localized PanNETs, both functioning and nonfunctioning, without distant metastasis.
Pathologists at the University of Ulsan College of Medicine (Seoul, Republic of Korea) assessed the significance of tumor border, a well-known prognostic indicator in other cancers, in the PanNETs. They evaluated the macroscopic growth pattern (expansile [Exp] versus infiltrative [Inf]) and the microscopic tumor border (pushing [Pus] versus Inf) of 203 surgically resected PanNETs and compared them with other clinicopathologic factors.
Growth pattern and tumor border were evaluated at the junctions between tumor and normal pancreatic parenchyma or between tumor and other adjacent organs by both gross and microscopic examination. First, macroscopic growth pattern was evaluated in PanNET cases with available gross images of the cut surface of the PanNETs and was classified as expansile or infiltrative pattern. Expansile growth pattern was defined when the tumor had well-delineated margin from adjacent parenchyma. Microscopic tumor border was categorized as pushing or infiltrative. When the tumor boundary was well circumscribed under microscopic examination, this was referred to as a pushing border. Tissue microarray (TMA) was constructed from archived, formalin-fixed, paraffin-embedded tissue blocks with a manual tissue microarrayer (UNITMA Co Ltd, Seoul, Korea).
The scientists reported that based on macroscopic growth pattern, 83 cases had Exp patterns whereas 84 had Inf patterns. According to microscopic tumor border, 122 PanNETs had Pus borders whereas 81 had Inf borders. Combining macroscopic growth pattern and microscopic tumor border, 65 PanNETs had Exp/Pus, 34 had Inf/Pus, 18 had Exp/Inf, and 50 had Inf/Inf status. PanNETs with Inf/Inf status were associated with higher tumor grade, pT classification, and American Joint Committee on Cancer stage grouping; lymph node metastasis; and lymphovascular and perineural invasion.. Patients with PanNET having Inf/Inf status had significantly shorter overall survival (OS) and recurrence-free survival (RFS). Further, using multivariate analysis, Inf/Inf status was identified as an independent poor prognostic factor of OS and RFS.
The authors concluded that the combined Inf/Inf status was observed in approximately 25% of PanNETs and was associated with aggressive biological behavior and short OS and RFS. Therefore, assessing combined macroscopic growth pattern and microscopic tumor border can provide additional information regarding survival and recurrence in PanNET patients. The study was published on May 9, 2022 in the journal Archives of Pathology and Laboratory Medicine.
Related Links:
University of Ulsan College of Medicine
UNITMA Co Ltd
Latest Pathology News
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
- Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
- Machine Learning Cytology Tool Improves Cancer Cell Identification
- CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
- Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
- AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
- Hybrid Computational Imaging Method Improves Digital Pathology Resolution
- FDA Clearance Expands Digital Pathology Options for Clinical Laboratories
- Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
- AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
- New Journal Addresses Evolving Needs in Clinical and Translational Pathology
Channels
Clinical Chemistry
view channel
Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome
Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more
Study Questions Broad Fasting Requirements Before Routine Blood Tests
Routine blood testing is central to diagnosis, monitoring, and disease risk assessment. Many patients are still asked to fast for 8–12 hours before phlebotomy, even though the requirement was originally... Read more
Elevated Lipoprotein(a) Linked to Long-Term Progression of Carotid Atherosclerosis
Lipoprotein(a), or Lp(a), is a genetically determined blood lipid and an important risk factor for cardiovascular disease. Its relationship to long-term carotid atherosclerosis has remained unclear, particularly... Read moreMolecular Diagnostics
view channel
Genomic Screening Expands Detection of Treatable Conditions in Newborns
Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more
Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants
Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more
New NGS Suite Expands Clonality and MRD Research in Lymphoid Malignancies
Lymphoid malignancies require molecular tools that can distinguish clonal immune receptor rearrangements and track disease-related sequences over time. As immune receptor measurable residual disease analysis... Read more
Tumor-Informed ctDNA Test Shows Utility Across Gastrointestinal and Gynecologic Cancers
Natera announced new data on Signatera, its tumor-informed circulating tumor DNA test, that were presented in four oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Prototype Point-of-Care Test Aims to Improve Neonatal Sepsis Diagnosis
Neonatal sepsis remains difficult to diagnose because early signs can resemble other newborn conditions. Diagnostic delays may increase the risk of complications, death, long-term adverse outcomes, and... Read more
Single-Tier Lyme Disease Test Shows High Sensitivity in Early Infection
Lyme disease can be difficult to diagnose during the earliest stages of infection, when conventional serologic testing may have limited sensitivity. Patients may present during a diagnostic gray zone in... Read moreMicrobiology
view channel
Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more
Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more
Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China
Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
CellCarta (Montreal, Canada) and Imagene AI (Miami, FL, USA) have expanded their collaboration to provide biopharma companies with a coordinated pathway for biomarker strategy, assay development, validation,... Read more







